Statement of Changes in Beneficial Ownership (4)
February 09 2022 - 5:36PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Helash Kevin |
2. Issuer Name and Ticker or Trading Symbol
MARRONE BIO INNOVATIONS INC
[
MBII
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
(Last)
(First)
(Middle)
C/O MARRONE BIO INNOVATIONS, INC., 7780-420 BRIER CREEK PARKWAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/7/2022 |
(Street)
RALEIGH, NC 27617-7882
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/7/2022 | | A | | 178831 (1) | A | $0.6321 | 241568 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $0.6321 | 2/7/2022 | | A | | 417273 | | 3/7/2022 (2) | 2/6/2025 (2) | Common Stock | 417273 | $0.00 | 417273 | D | |
Explanation of Responses: |
(1) | On February 7, the reporting person was granted 178,831 restricted stock units, which represent a contingent right to receive one share of Issuer's common stock. The restricted stock units vest pursuant to the Vesting Schedule (as defined in footnote (2)) and are delivered to the reporting person upon vesting. |
(2) | The awards vest in equal monthly installments over three years, subject to the recipient's continued employment by the Issuer through the applicable vesting date, provided that, in lieu of the terms of any change in control agreement in place between the Issuer and the reporting person, in the event that the reporting person resigns for Good Reason (as defined in the recipient's change in control agreement) or is terminated without Cause (as defined in recipient's change in control agreement) within twelve months of a Change in Control (as defined in recipient's change in control agreement), 50% of the unvested portion of the awards will become immediately vested (the "Vesting Schedule"). |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Helash Kevin C/O MARRONE BIO INNOVATIONS, INC. 7780-420 BRIER CREEK PARKWAY RALEIGH, NC 27617-7882 | X |
| Chief Executive Officer |
|
Signatures
|
/s/ Linda V. Moore, as attorney in fact | | 2/9/2022 |
**Signature of Reporting Person | Date |
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024